capmatinib
Ligand Summary
Capmatinib is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.
UNII: TY34L4F9OZ
PubChem: 25145656
Guide to Pharmacology: 7904
ChEMBL: CHEMBL3188267
DrugCentral: 5392
LyCHI: KLGQTGH34Q2A
Target Activities
5 Activities
Items per page:
1 – 5 of 5
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
---|---|---|---|---|---|---|
IC50 | ||||||
IC50 | ||||||
Kd | ||||||
IC50 | ||||||
IC50 | INHIBITOR | |||||